As far as valuation and revenue estimates are conc
Post# of 36568
(Total Views: 348)
Posted On: 06/25/2020 7:50:35 AM
As far as valuation and revenue estimates are concerned....for NGIO....this company has decades in oncology....research wise....and the 10 year data is conclusive to a beautiful fact, that the AE37 works with Triple negative and her 2 positive Breast cancer patients in advanced mode of toxicity....
investors only look at this (AE37 83.0% vs Control 62.5%, p = 0.039, HR 0.375).....and will be willing to put some dinero into this venture....just a hint of the Merck collaboration will bring in millions into the NGIO coffers....when it is on NASDAQ....we did not see a similar run because we are an OTC company....and many financial houses will not invest in a sub 5 $ par company, better yet a penny stock....
so i do think that an approximate valuation will be handy, but i believe it is costly and may not be necessary right now.....hence why Joe has not put that forth as of yet....maybe he will, depending on the advise of the IPO underwriters....
Reference...
https://storage.googleapis.com/wzukusers/user...8_2020.pdf
investors only look at this (AE37 83.0% vs Control 62.5%, p = 0.039, HR 0.375).....and will be willing to put some dinero into this venture....just a hint of the Merck collaboration will bring in millions into the NGIO coffers....when it is on NASDAQ....we did not see a similar run because we are an OTC company....and many financial houses will not invest in a sub 5 $ par company, better yet a penny stock....
so i do think that an approximate valuation will be handy, but i believe it is costly and may not be necessary right now.....hence why Joe has not put that forth as of yet....maybe he will, depending on the advise of the IPO underwriters....
Reference...
https://storage.googleapis.com/wzukusers/user...8_2020.pdf
(0)
(0)